(Q42278490)

19 October 2017

title

Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission (English)

1 reference

19 October 2017

0 references

0 references

C E Shaw

1

1 reference

19 October 2017

P R Dunbar

series ordinal

2

1 reference

19 October 2017

H A Macaulay

series ordinal

3

1 reference

19 October 2017

T J Neale

series ordinal

4

1 reference

19 October 2017

publication date

1 January 1995

1 reference

19 October 2017

1 reference

19 October 2017

volume

242

1 reference

19 October 2017

issue

2

1 reference

19 October 2017

page(s)

53-58

1 reference

Significantly higher levels of soluble interleukin 2 in patients with relapsing-remitting multiple sclerosis compared with healthy subjects

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF00887815

T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00887815

Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00887815

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00887815

The soluble interleukin-2 receptor: biology, function, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00887815

CSF neopterin as marker of disease activity in multiple sclerosis

21 January 2018

1 reference

12 December 2020

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

1 reference

12 December 2020

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

1 reference

12 December 2020

Prospective serial analysis of interleukin-2 and soluble interleukim-2 receptor in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours

1 reference

12 December 2020

Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis

1 reference

12 December 2020

Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients

1 reference

12 December 2020

Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis

1 reference

12 December 2020

On the evaluation of disability in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor

1 reference

12 December 2020

Neopterin in clinical practice

1 reference

12 December 2020

Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis

1 reference

12 December 2020

Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels

1 reference

12 December 2020

Tumor necrosis factor-alpha enhances interferon-gamma-mediated class II antigen expression on astrocytes

1 reference

12 December 2020

Demonstration of alpha, beta, and gamma interferon in active chronic multiple sclerosis lesions

1 reference

12 December 2020

Elevated levels of soluble interleukin-2 receptors in multiple sclerosis

1 reference

12 December 2020

Significance of CSF total neopterin and biopterin in inflammatory neurological diseases

1 reference

12 December 2020

Immunological treatment for multiple sclerosis

1 reference

12 December 2020

Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis

1 reference

12 December 2020

Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility

1 reference

12 December 2020

Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis

1 reference

12 December 2020

Interferon-γ potentiates antibody-mediated demyelination in vivo

1 reference

12 December 2020

Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis

1 reference

12 December 2020

In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

1 reference

12 December 2020

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

12 December 2020

Elevated interleukin 2 levels in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

12 December 2020

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

1 reference

12 December 2020

In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

1 reference

12 December 2020

Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients

1 reference

12 December 2020

Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid

1 reference

12 December 2020

Cerebrospinal fluid levels of myelin basic protein-like material and soluble interleukin-2 receptor in multiple sclerosis

1 reference

12 December 2020

Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue

1 reference

12 December 2020

1 reference

12 December 2020

Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders

1 reference

12 December 2020

A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00887815

1 reference

19 October 2017

1 reference